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Abstract Activation of complement cascade (ComC) play
and important role in mobilization of hematopoietic stem/
progenitor cells (HSPCs) from bone marrow (BM) into pe-
ripheral blood (PB). While there are vast experimental data on
the mechanisms and factors that induce or promote mobiliza-
tion of HSPCs, there is relatively less data on negative regu-
lators of this process. We demonstrate for the first time that
heme oxygenase-1 (HO-1) that has a well-documented anti-
inflammatory potential plays an important and heretofore
unrecognized role in retention of HSPCs in BM niches by i)
modulating negatively activation of mobilization promoting
ComC, ii) maintaining stromal derived factor-1 (SDF-1) level
in the BM microenvironment and iii) attenuating chemotactic
responsiveness of HSPCs to SDF-1 and sphingosine-1 phos-
phate (S1P) gradients in PB. Furthermore, our data showing a
positive mobilizing effect by a non-toxic small-molecule in-
hibitor of HO-1 (SnPP) suggest that blockade of HO-1 would
be a promising strategy to facilitate mobilization of HSPCs.
Further studies are also needed to evaluate better the
molecular mechanisms responsible for the potential effect of
HO-1 in homing of HSPCs after transplantation.
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Introduction
While there are vast experimental data in the literature on the
mechanisms and factors that induce or promote mobilization
of hematopoietic stem/progenitor cells (HSPCs) from bone
marrow (BM) into peripheral blood (PB), there is relatively
less data on negative regulators of this process. Inhibitory
effects on mobilization have been described mainly for serine
protease inhibitors (serpins) [1] and tissue inhibitors of metal-
loproteinases (TIMPs) [2].
It is well known that HSPCs are retained in BM niches due
to interaction between the chemokine CXCR4 receptor and
very late antigen-4 (VLA-4, also known as α4β1 integrin),
which are expressed on the surface of HSPCs. Their respec-
tive ligands, α-chemokine stromal-derived growth factor-1
(SDF-1) and vascular adhesion molecule-1 (VCAM-1, also
known as CD106), are expressed by cells in the BM stem cell
niches (e.g., osteoblasts and fibroblasts) [3–6]. HSPCs circu-
late under steady-state conditions at detectable levels in the
PB, and their number increases in PB in response to i) sys-
temic or local inflammation, ii) stress, iii) tissue/organ injury,
iv) strenuous exercise, and v) certain pharmacological agents
such as granulocyte colony-stimulating factor (G-CSF) or the
CXCR4 small-molecule antagonist AMD3100 [3–6]. All the-
se processes trigger activation of complement cascade
(ComC) [5].
Harvested from PB, pharmacologically mobilized HSPCs
are a convenient source of cells for hematopoietic
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transplantation. It is well known that mobilization induces a
proteolytic microenvironment in BM, and the mobilization
process is promoted, at least in part, by the effect of proteolytic
enzymes on attenuating SDF-1–CXCR4 andVLA-4–VCAM-
1 interactions in the BM microenvironment [3–6].
Specifically, several proteolytic enzymes involved in mobili-
zation of HSPCs are released from activated granulocytes and
monocytes residing in BM. However, the fact that mice with
knockouts of proteolytic enzymes, such as MMP-9, cathepsin
G, and elastase, are normal mobilizers [7] indicates that this
list is incomplete and suggests the involvement of other pro-
teolytic enzymes secreted by BM-residing cells or even, as we
recently proposed, the involvement of proteolytic cascades
such as the complement cascade (ComC), coagulation cascade
(CoaC), and fibrynolytic cascade (FibC) [8]. All these ancient
proteolytic cascades are activated in response to stress situa-
tions, inflammation, and administration of mobilizing agents
(e.g., G-CSF and AMD3100) [5].
In previous work, we reported a crucial role for the fifth
protein component of ComC (C5) in mobilization of HSPCs
[9]. C5-deficient mice are very poor mobilizers, and to explain
this, we postulated that C5 cleavage fragments (C5a and C5b)
are essential for egress of HSPCs from BM into PB. While
C5a anaphylatoxin i) activates neutrophils and monocytes in
the BM microenvironment to secrete proteolytic enzymes, ii)
permeabilizes endothelium, and iii) chemoattracts neutrophils
and monocytes into PB [9], the C5b-C9 complex (also known
as membrane attack complex, MAC) releases from erythro-
cytes and platelets sphingosine-1-phosphate (S1P), which is a
major chemoattractant for HSPCs in PB [10]. Therefore, we
proposed that innate immunity (e.g., the functions of
granulocytes and activated ComC) and the accompanying
inflammatory process is a trigger for egress of HSPCs from
BM into PB [5].
Since activated ComC is a trigger for mobilization and
induces a proteolytic environment in BM, oxidative stress,
activation of platelets, and damage to erythrocyte membranes,
we became interested in mechanisms that control and attenu-
ate this process. Heme oxygenase 1 (HO-1) is an inducible
stress-responsive enzyme that not only catalyzes the degrada-
tion of heme (e.g., released from erythrocytes exposed to
MAC) but also plays an important function in various phys-
iological and pathophysiological states associated with cellu-
lar stress such as ischemic/reperfusion injury [11]. HO-1 has a
well-documented anti-inflammatory potential and inhibits
ComC-dependent inflammation by upregulating as reported
expression of ComC inhibitors CD55 and CD59 on endothe-
lial cells [12], and HO-1 deficiency in humans and mice
results in vulnerability to stressful injury [11]. Interestingly,
it has also been reported that HO-1 directly regulates the
expression of SDF-1 [13], which, as mentioned above, pro-
vides a major retention signal for HSPCs in BM niches [3–6].
Moreover, HO-1 has been reported to have negative effect on
adhesion and migration of neutrophils in acute inflammation
[14]. Neutrophils are first cells that egress BM during mobi-
lization and as we demonstrated are crucial to pave a way for
HSPCs across BM-blood barrier [9].
To address the role of HO-1 in retention and mobilization
of HSPCs in BM, we performed mobilization studies in HO-1
knockout mice (HO-1+/− and HO-1−/−).
Material and Methods
Animals In our studies we employed wild-type (+/+), hetero-
zygous (+/−), or homozygous null (−/−) mice for targeted
disruption of HO-1 [15]. These mice were maintained on a
129Sv×BALB/c genetic background, and littermates were
used for the studies [15]. For some experiments additional
mice C57BL/6 were purchased from Jackson Laboratories
(Bar Harbor, ME). Animal studies were approved by the
Animal Care and Use Committee of the University of
Louisville (Louisville, KY).
Mobilization Mice were mobilized by subcutaneous injection
of 100 μg/kg human G-CSF (Amgen, Thousand Oaks, CA)
daily for 3 or 6 days; or single intraperitoneal injection of
AMD3100 5 ug/kg (Sigma, St. Louis, MO). Six hours after
the last G-CSF injection or 2 h post AMD3100 injection, PB
was obtained from the vena cava (with a 25-gauge needle and
1-mL syringe containing 250 U heparin). MNC cells were
obtained by hypotonic lysis of red blood cells in BD Pharm
Lyse buffer (BD Biosciences, San Jose, CA) as described
[8–10]. In some mobilization protocols the HO-1 inhibitor
protoporphyrin IX (SnPP-IX) (Porphyrin Products, Logan,
UT, USA) was injected intraperitoneally (30 mg/kg) one hour
before G-CSF or AMD3100 injections.
WBCCounts Fifty microliters of PBwas taken from the retro-
orbital plexus of the mice and collected into microvette
EDTA-coated tubes (Sarstedt Inc., Newton, NC). Samples
were run within 2 h of collection on a HemaVet 950 (Drew
Scientific Inc., Oxford, CT) as described [8–10].
Colony Forming Unit-Granulocytes/Macrophage (CFU-GM)
Assay for Circulating in PB HSPCs Red blood cells (RBCs)
were lysed with BD Pharm Lyse buffer (BD Biosciences, San
Jose, CA). Nucleated cells from PB were subsequently
washed twice and used for CFU-GM colonies, cells were
resuspended in human methylcellulose base media provided
by the manufacturer (R&D Systems, Inc., Minneapolis, MN)
supplemented with 25 ng/ml recombinant murine granulocyte
macrophage colony-stimulating factor (mGM-CSF) and
10 ng/ml recombinant murine interleukin-3 (mIL-3;
Millipore, Billerica, MA). Cultures were incubated for 7 days,
at which time they were scored for the number of CFU-GM
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colonies under an inverted microscope as described [8–10].
We cultured 1×106 PBMNC/dish and final results are
recalculated based on number of PBMNC/1 μl of peripheral
blood.
Fluorescence-Activated Cell Sorting (FACS) Analysis BMNC
staining was performed in medium containing 2 % fetal bo-
vine serum (FBS). All monoclonal antibodies (mAbs) were
added at saturating concentrations and the cells were incubat-
ed for 30 min on ice, washed twice, resuspended in staining
solution at a concentration of 5×106 cells/ml, and subjected to
analysis using an LSR II (Becton Dickinson, Mountainview,
CA). The following anti-mouse Abs were used to detect
fluorescein isothiocyanate (FITC)-anti-CD117 (c-Kit) (clone
2B8; BioLegend, San Diego, CA) and Phycoerythrin (PE)-
Cy5 anti-mouse Ly-6A/E (Sca-1) (clone D7; eBioscience™,
San Diego, CA). All anti-mouse lineage markers (Lin) were
conjugated by PE and purchased from BD Biosciences: anti-
CD45R/B220 (clone RA3-6B2); anti-Gr-1 (clone RB6-8C5);
anti-T-cell receptor β (TCRβ; clone H57-597); anti-TCRγδ
(clone GL3); anti-CD11b (clone M1/70); anti-Ter-119 (clone
TER-119); and anti-CD34 (clone RAM34) as described
[8–10].
Evaluation of HSPCMobilization The following formula was
used for evaluation of circulating CFU-GM and Sca-1+/c-
Kit+/Lin−/CD34− (SKL CD34−) cells: {[number of white
blood cells (WBCs) × number of CFU-GM colonies]/number
of WBCs plated = number of CFU-GM per microliter of PB}
and {(number of WBCs × number of SKL CD34− cells)/
number of gated WBCs = number of SKL cells per microliter
of PB}, respectively [8–10].We cultured 1×106 PBMNC/dish
and final results are recalculated based on number of PBMNC/
1 μl of peripheral blood.
Colony-Forming Assays To evaluate the number of congenic
progenitor cells BMMNC were resuspended in methylcellu-
lose basemedia provided by the manufacturer (R&DSystems,
Inc., Minneapolis, MN) supplemented with granulocyte mac-
rophage colony-stimulating factor (GM-CSF, 25 ng/ml) plus
interleukin-3 (IL-3, 10 ng/ml) for colony forming units (CFU)
granulocyte/macrophage (GM), erythropoietin (EPO, 5 unit/
ml, Stem Cell Tech) plus stem cell factor (SCF, 5 ng/ml) for
burst-forming units (BFU-E), and thrombopoietin (TPO,
100 ng/ml) for CFU-megakaryocytes (Megs). All growth
factors were purchased from the same company unless other-
wise mentioned. Cultures were incubated for 7 days, at which
time they were scored under an inverted microscope for the
number of each colonies as described [10].
Real-Time Quantitative Reverse-Transcription PCR Total
RNA was isolated from HO-1+/+ (WT), HO-1+/− and HO-1−/
− mice BMMNC or BM stroma cells with the RNeasy kit
(Qiagen, Valencia, CA). The RNA was reverse transcribed
with MultiScribe reverse transcriptase, oligo(dT), and
random-hexamer primer mix (Applied Biosystems, Foster
City, CA). PCR was performed at 2 cycles of 2 min at
95 °C, 1 min at 60 °C, and 1 min at 72 °C; 36 cycles of 30 s
at 95 °C, 1 min at 60 °C, and 1 min at 72 °C; and 1 cycle of
10min at 72 °C. Quantitative assessment of mRNA levels was
done by real-time reverse transcription PCR (RT-PCR) on an
ABI 7500 instrument with Power SYBR Green PCR Master
Mix reagent. Real-time conditions were as follows: 95 °C
(15 s), 40 cycles at 95 °C (15 s), and 60 °C (1 min). We
Fig. 1 HO-1 does not affect
hematological homeostasis. Bone
marrow ofWT (HO-1+/+), HO-1+/
− and HO-1−/− mice was isolated
and evaluated for number of
CFU-GM (i), BFU-E (ii) and
CFU-MEG (iii) in clonogenic
in vitro assays. Peripheral blood
parameters were evaluated by
Hemavet and indicated no
differences in number of white
blood cells (WBC), neutrophils
(NE), lymphocytes (LY),
monocytes (MO) and red blood
cells (RBC) (iv). HO-1 deficiency
had no effect on hemoglobin
(HB) content and hematocrit
(HCT) (v). Data represent at
average of at least eight mice per
experimental group
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employed following primers: CXCR4 (forward): GTA CCG
GCT GCA CCT GTC A, CXCR4 (reverse): CAA AAATTT
CCC AAA GTA CCA G, SDF-1 (forward): TCT GCATCA
GTG ACG GTA A and SDF-1 (reverse): GAG TGT TGA
GGA TTT TCA G, β-2D (forward): TCC AGC TGT TGG
AAG TTT AAA AAG T β-2D (reverse): AGG ACA AAT
GGC TCT GAC ACA GT. According to melting point anal-
ysis, only one PCR product was amplified under these condi-
tions. The relative quantity of a target, normalized to the
endogenous β2-microglobulin gene as control and relative
to a calibrator, is expressed as 2−ΔΔCt (fold difference), where
Ct is the threshold cycle, ΔCt = (Ct of target genes) − (Ct of
the endogenous control gene, β2-microglobulin), and ΔΔCt
= (ΔCt of samples for target gene) − (ΔCt of calibrator for the
target gene) as described [10].
Trans-Well Migration Assay The trans-well migration assay
was performed as described elsewhere [10]. Briefly, un-
less otherwise indicated, murine RBC-lysed BMNCs were
resuspended in assay media (RPMI containing 0.5 %
BSA) and equilibrated for 10 min at 37 °C. Assay medi-
um (650 μl) containing test reagents was added to the
lower chambers of a Costar Trans-well plate (Costar
Corning, Cambridge, MA, USA). Aliquots of cell suspen-
sion (5×105 cells/100 μl) were loaded onto the upper
chambers with 5 μm-pore filters, then incubated for 3 h
(37 °C, 5 % CO2). Cells from the lower chambers were
scored using FACS analysis for migration of BMNCs to
test reagents and plated in CFU-GM colony assays as
described [10].
Adhesion HSPC to BM Stroma BMMNC cells from WT and
HO-1 deficient mice were tested for adhesion to WTor HO-1
deficient BM stroma cells as described [16]. In our assay 105
BMMNC cells of each genotype were plated over stroma
cells. After 30 min of adhesion, non-adherent cells were
discarded from the adhesion cultures and the cells in the wells
were trypsinzed and subsequently plated in methylocellulose
cultures stimulated to grow CFU-GM colonies as described
[16]. Since marrow fibroblasts were irradiated before the
Fig. 2 HO-1 deficiency reduces adhesive potential of bone marrow
stromal cells. Panel a - Bone marrow mononuclear cells (BMMNC)
and BM stromal cells were derived from bone marrow of HO-1+/+
(WT), HO-1+/− and HO-1−/− mice. Total RNAwas isolated and quantita-
tive real-time PCR was performed to determine expression of CXCR4 in
BMMNC and SDF-1 and beta defensine-2 expression in BM stroma
cells. * p<0.05. Panel b – ELISA results demonstrating decrease in
SDF-1 level in conditionedmedia harvested fromBMstroma cell cultures
from HO-1 deficient animals. * p<0.05. Panel c - HO-1 does not affect
adhesion of CFU-GMs to stromal cells isolated fromwild typemice (left),
however wild type CFU-GM have impaired adhesion to stromal cells
isolated from HO-1+/− and HO-1−/− mice in comparison to HO-1+/+
(WT) (right). * p<0.05. Number of CFU-GM colonies that adhered to
stroma cells in left and right panel were assumed to be 100 %. Data
represent average of three independent experiments (a–c)
Fig. 3 Loss of HO-1 function augments mobilization of bone marrow
HSPC. The role of HO-1 in bone marrow stem cells mobilization was
studied in HO-1 knockout mice (Panel a and b) and in wild type mice
treated with HO-1 inhibitor SnPP (Panel c and d). Mice were mobilized
with G-CSF for 3 and 6 days (100 μg/kg/day subcutaneously) (Panel a
and c) and single dose of AMD3100 (5μg/kg, intraperitoneally) (panel b
and d). Mobilization was evaluated by number of circulating WBCs (i),
clonogenic in vitro CFU-GMs (ii) and Sca-1+ c-kit+ Lin− (SKL) cells by
flow cytometry (iii) per microliter of peripheral blood. * p<0.05. Data
represent average of three independent experiments with at least four
mice per experimental group
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adhesion assay, they did not grow after plating in
methylcellulose.
Plasma Concentration of C5b-C9 (MAC Complex) The con-
centration of C5b-C9 was measured by employing the com-
mercially available, highly sensitive ELISA kit K-ASSAY
(Kamiya Biomedical Company, Seattle, Wa), according to
the manufacturer’s protocol as described [8]. For analysis
peripheral blood from C3 −/− mice was collected at day sixth
of G-CSF-induced mobilization by the retro-orbital plexus
bleeding into cold microvette EDTA-coated tubes (Sarstedt
Inc., Newton, NC). Subsequently, blood was centrifuged
2000×g for 20 min in 4 °C to obtain plasma.
SDF-1 Measurement Assay
SDF-1 levels were evaluated in conditioned media from BM
stroma cells and in PB plasma by sandwich ELISA using the
commercially available ELISA system (R&D Systems,
Minneapolis, MN, USA) as described [10].
Statistics All results were presented as mean±SD. Statistical
analysis of the data was done using Student’s t test for un-
paired samples, with p<0.05 considered significant.
Results and Discussion
To address the role of HO-1 in retention and mobilization of
HSPCs in BM, we employed as an experimental model HO-1
knockout mice (HO-1+/− and HO-1−/−) [15]. It has been re-
ported that these animals with advancing age develop anemia
[17]. However we noticed that HO-1+/− and HO-1−/− mice at
the age of 6–8 weeks maintained in our colony still have the
same number of hematopoietic progenitors in peripheral blood
and peripheral blood counts as wild type (WT) littermates
(Fig. 1). Therefore, since, this equivalence changes with
Fig. 4 Panel a. Activation of ComC as measured by increase in concen-
tration of C5a cleavage fragments in PB. Control values in non-mobilized
WT mice were assumed to be 1.0. Mice were mobilized with G-CSF for
6 days (50 μg/kg/day subcutaneously). * p<0.05 as compared to WT
mice. Panel b – Chemotactic responsiveness of Gr-1+ granulocytes from
control and HO-1-defcient mice. Chemotaxis to SDF-1 (300 ng/ml), C5a
(120 ng/ml), desArgC5a (140 ng/ml) and S1P (0.1 μM)was perfomed with
Gr-1+ cells purified from HO-1+/+ (WT), HO-1+/− and HO-1−/− mice and
number of cells that migrated spontaneously to lower chambers contain-
ingmedium only was assumed to be 100%. * p<0.05 as compared toWT
mice. Panel c. HO-1 deficiency increases chemotactic activity of bone
marrow HSPC. Chemotaxis to SDF-1 (300 ng/ml) or S1P (0.1 μM)
gradient was performed with bone marrow mononuclear cells isolated
fromHO-1+/+ (WT), HO-1+/− andHO-1−/−mice and number of CFU-GM
that migrated to SDF-1 or S1P in HO-1+/+ (WT) was assumed to be
100 %. Number of CFU-GM migrated to SDF-1 gradient was evaluated
in clonogenic assay in methylcellulose cultures in presence of IL-3 (5 ng/
mL) and GM-CSF (5 ng/mL). * p<0.05. Data represent average of three
independent experiments performed in triplicate. Panel c. HO-1 inhibi-
tion by SnPP enhances migration of normal CFU-GM to SDF-1 gradient.
Number of CFU-GM that migrated to SDF-1 (300 ng/ml) gradient in
absence or presence of SnPP (25 μM) was evaluated in clonogenic assay
in methylcellulose cultures in presence of IL-3 (5 ng/mL) and GM-CSF
(5 ng/mL). * p<0.05. Data represent average of three independent exper-
iments performed in triplicate. Migration of cells to SDF-1 gradient has
been assumed to be 100 %
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advancing age we performed our mobilization studies
employing mice that were 6–8 weeks old.
Based on report that HO-1 directly regulates the expression
of SDF-1 in ischemic heart [13], we employed RQ-PCR, and
found that HO-1 deficiency results in a significant decrease in
expression of SDF-1 in BM stromal cells. We also noticed
decrease in expression of β2-defensin (β2-D) that is a mod-
ulator of responsiveness of HSPCs to SDF-1 gradient [5]. At
the same time expression of CXCR4 that is SDF-1 binding
receptor in BM mononuclerar cells (BMMNC) was unaffect-
ed (Fig. 2a). A decrease in SDF-1 at mRNA (Fig. 2a) and at
protein level in bone marrow stroma cells (Fig. 2b) corrobo-
rates the observation that HO-1 regulates the SDF-1 level in
myocardium [13]. This observation together with the decrease
in expression of β2-D, which positively modulates the
responsiveness of HSPCs to an SDF-1 gradient [5], indicates
a potential defect in retention of HSPCs in BM niches in HO-
1-deficient mice. The existence of this defect was further
supported by defective adhesion of WT HSPCs in stromal
cells of HO−/− mice (Fig. 2c). Nevertheless, since HO-1 defi-
cient mice have in steady state conditions a similar number of
circulating SKL and CFU-GM cells in PB as WT littermates
indicates that at age of 6–8 weeks retention of HSPCs in BM
in mutant animals is not affected and compensated by other
BM retention axes (e.g., VLA-4 – VCAM-1) [3–7].
To evaluate BM retention of HSPCs in these animals under
stress-directed conditions we performed direct mobilization
studies employing G-CSF (Fig. 3a) and AMD 3100 (Fig. 3b)
and noticed that HO-1-deficient mice easily mobilize HSPCs
into PB according to the degree of HO-1 deficiency
Fig. 5 Proposed involvement of HO-1-deficiency in mobilization pro-
cess of HSPCs. There are four levels at which HO-1-defciencymay affect
HSPC mobilization. Level 1 - decrease in SDF-1-mediated BM retention
signal for HSPCs as result of i) decrease in SDF-1 expression by BM
stroma cells and ii) as result of an enhanced activation of ComC that leads
to C5mediated stimulation of granulocytes in the BMmicroenvironment.
Granulocytes in response to C5a and desArgC5a secrete proteolytic en-
zymes that additionally perturb HSPCs retention signals (e.g., SDF-1-
CXCR4 and VLA-4-VCAM-1 interactions).Level 2 – hyperactivation of
ComC results in increase in C5a and desArgC5a and S1P levels in blood
plasma. Level 3 - serum C5a and desArgC5a chemoattract from BM
granulocytes that “pave the way” for HSPCs, which follow granulocytes
and migrate through the endothelial barrier (“ice breaker phenomenon”)
Level 4 - HSPCs released from their niches respond to serum S1P and
egress from BM. Finally, we cannot exclude the potential role of HO-1 on
permeabilization status of the BM sinusoids endothelium, which will
require further studies
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(HO-1−/−>HO-1+/−>WT). A similar effect was obtained in
WT mice in which we inhibited HO-1 by i.p. administration
of the HO-1 small-molecule inhibitor tin protoporphyrin IX
(SnPP) (Fig. 3c and d). As reported in the past [10] mobiliza-
tion of HSPCs into PB was not related to changes in plasma
level of SDF-1 (Supplementary Figure 1A). Importantly, an
enhanced mobilization of HSPCs in HO-1-deficient mice was
correlated with enhanced activation of ComC in PB in re-
sponse to G-CSF (Fig. 4a).
Several positive modulators of mobilization have been
described [3–6], while little is known about pathways that
negatively modulate this process. Our data for the first time
identifies HO-1 as an important negative modulator of HSPC
mobilization. Based on published literature we hypothesized
that enhancedmobilization in HO-1-defcient mice is related to
i) a decrease in SDF-1 level in BM stroma and thus impaired
retention of HSPCs in BM niches [15], ii) a lack of anti-
inflammatory effect of HO-1 [11] that leads to enhanced
activation of mobilization promoting ComC and iii) enhanced
motility of HO-1-defective cells [14].
In support of this, Gr-1+ neutrophils sorted from HO-1-
defcient mice (Supplementary Figure 1B), that are well known
as first cells that egress during BM during mobilization in
order to pave a way for HSPCs across blood-BM barrier [9]
showed enhanced chemotactic responsiveness to C5a and
desArgC5a gradient (Fig. 4b). More important we demonstrate
for a first time that also HSPCs from HO-1-deficient mice
present enhanced migration toward SDF-1 and S1P gradient
(Fig. 4c). These observations corroborate with report that HO-
1 is negative regulator of neutrophil migration [14]. To sup-
port this further we performed Transwell migration assay and
demonstrated that inhibition of HO-1 by non-toxic small-
molecule inhibitor of HO-1 (SnPP) similarly as reported for
neutrophils [14] significantly enhanced Transwell migration
of HSPCs toward SDF-1 gradient (Fig. 4d).
Furthermore, since ComC plays a crucial role in mobiliza-
tion of HSPCs [5, 8–10] and overexpression of HO-1
upregulates as reported expression of one of the ComC inhib-
itors, decay-accelerating factor (DAF or CD55) on the surface
of erythrocytes [12], we explored a possibility that one of anti-
mobilizing effects of HO-1 could be related to this effect.
However, we did not observed any differences in expression
of DAF/CD55 on surface of erythrocytes between HO-1
deficient and normal mice (data not shown).
As we have demonstrated here, HO-1-deficient mice are
easymobilizers, which could be at least partially the result of a
decrease in SDF-1 level in BM stroma and defective retention
of HSPCs in BM niches (Fig. 2). Interestingly, it has been
reported [16] mice lacking one allele of HO-1 (HO-1+/−)
showed accelerated hematopoietic recovery from myelotoxic
injury, and HO-1+/− HSCs repopulated lethally irradiated re-
cipients with more rapid kinetics. This effect of accelerated
hematopoietic recovery of HO-1+/− mice can be explained by
the possibility that defective retention of HSPCs prevents their
niche-mediated quiescence in BM and may promote their
expansion as demonstrated elegantly in mice transplanted
with CXCR4 blocking agent [18].
In conclusion, our data demonstrate for the first time that
HO-1 plays an important and heretofore unrecognized role in
modulating positively SDF-1 levels in the BM microenviron-
ment and thus plays a role in SDF-1-mediated retention of
HSPCs in BM niches. What we also show here for first time is
that HO-1 is a negative regulator of responsiveness of HSPCs
to chemotactic gradients, and that HSPCs fromHO-1 deficient
mice respond robust to S1P that is a major chemoattractant for
HSPCs in PB [10, 19]. HO-1 deficient mice are easy
mobilizers and HO-1 negatively affects egress of HSPCs from
BM at least partially by attenuating ComC activation what
provides also further support for a pivotal role of ComC in
mobilization of HSPCs. Our interpretation of HO-1 involve-
ment in stem cell mobilization is graphically depicted at
Fig. 5. Furthermore, our data showing a mobilizing effect by
a non-toxic small-molecule inhibitor of HO-1 (SnPP) suggest
that blockade of HO-1 would be a promising strategy to
facilitate mobilization of HSPCs. Finally, based on enhanced
responsiveness of HO-1 deficient cells to SDF-1 gradient
further studies are also needed to understand better the mo-
lecular mechanisms responsible for the potential effect of HO-
1 in homing of HSPCs after transplantation.
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